Investor List:

Top BioTech Series B Investors in Raleigh-Durham / Southeast US (21)

Know someone who's actively diligencing and investing? Add them to this list.
About this list
We’ve compiled a list of the top BioTech investors. The goal is to help Founders find the best investors to target and get introduced to.
Photo of Scott Rocklage, Partner at 5am Ventures
Scott Rocklage
5am Ventures·Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in San Francisco (CA), Investors in SF Bay Area (CA), Investors in Menlo Park (CA), Investors in Palm Beach Gardens (FL)
Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in San Francisco Bay Area (Other Lists), Investors in BioTech (Series A), Investors in BioTech (Series B), Investors in BioTech (Series B), Investors in Raleigh-Durham / Southeast US (Other Lists)
Photo of Inga Deakin, Principal at Molten Ventures
Inga Deakin
Molten Ventures·Principal
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Raleigh (NC), Investors in London
Investors in Medical Devices (Seed), Investors in BioTech (Series B), Investors in Medical Devices (Series B), Investors in Medical Devices (Series A), Investors in BioTech (Seed), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in Health & Hospital Services (Series B), Investors in BioTech (Seed), Investors in BioTech (Seed), Investors in Health IT (Seed), Investors in Health IT (Seed), Investors in Medical Devices (Seed), Investors in Health & Hospital Services (Series A), Investors in Medical Devices (Seed), Investors in Health & Hospital Services (Seed), Investors in Health & Hospital Services (Seed), Investors in BioTech (Series A), Investors in BioTech (Series A), Investors in Health IT (Series A), Investors in Medical Devices (Series A), Investors in Health IT (Series A), Investors in Medical Devices (Series A), Investors in Health & Hospital Services (Series A), Investors in Health & Hospital Services (Series A), Investors in BioTech (Series B), Investors in BioTech (Series B), Investors in Health IT (Series B), Investors in Medical Devices (Series B), Investors in Health IT (Series B), Investors in Medical Devices (Series B), Investors in Health & Hospital Services (Series B), Investors in Health & Hospital Services (Series B), Investors in Raleigh-Durham / Southeast US (Other Lists), Investors in London (Other Lists), Investors in Digital Health (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Digital Health (Series A), Investors in Digital Health (Series B), Investors in Digital Health (Seed), Investors in Digital Health (Series B), Investors in Health IT (Seed), Investors in Health IT (Series B), Investors in Digital Health (Series A), Investors in Digital Health (Seed), Investors in Health & Hospital Services (Seed)
Photo of Tom Masterson, Managing Director at Allele Capital Partners
Tom Masterson
Allele Capital Partners·Managing Director
Sweet spot: $1.5M
Range: $100K - $5.0M
Photo of David Pierson, Managing Director at Syngenta Group Ventures
David Pierson
Syngenta Group Ventures·Managing Director
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Durham (NC)
Investors in AgTech (Series B), Investors in AgTech (Series A), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series B), Investors in AgTech (Seed), Investors in E-commerce (Series B), Investors in E-commerce (Series A), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series B), Investors in AgTech (Seed), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Seed), Investors in E-commerce (Seed), Investors in E-commerce (Seed), Investors in Pharmaceuticals (Seed), Investors in AgTech (Series A), Investors in BioTech (Series A), Investors in E-commerce (Series A), Investors in Pharmaceuticals (Series A), Investors in AgTech (Series B), Investors in BioTech (Series B), Investors in E-commerce (Series B), Investors in Pharmaceuticals (Series B), Investors in Raleigh-Durham / Southeast US (Other Lists)
Photo of Matt Hughes, Managing Director at Allele Capital Partners
Matt Hughes
Allele Capital Partners·Managing Director
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Boca Raton (FL)
Investors in Pharmaceuticals (Seed), Investors in BioTech (Series B), Investors in BioTech (Seed), Investors in Pharmaceuticals (Series B), Investors in FinTech (Series B), Investors in BioTech (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Seed), Investors in FinTech (Seed), Investors in Pharmaceuticals (Seed), Investors in BioTech (Series A), Investors in FinTech (Series A), Investors in Pharmaceuticals (Series A), Investors in BioTech (Series B), Investors in FinTech (Series B), Investors in Pharmaceuticals (Series B), Investors in Raleigh-Durham / Southeast US (Other Lists), Investors in FinTech (Series A), Investors in FinTech (Seed)
Photo of Ankit Bhargava, Managing Director at Allele Capital Partners
Ankit Bhargava
Allele Capital Partners·Managing Director
Sweet spot: $1.5M
Range: $100K - $5.0M
Photo of Menachem Kranz, Managing Partner at Allele Capital Partners
Menachem Kranz
Allele Capital Partners·Managing Partner
Sweet spot: $1.5M
Range: $100K - $5.0M
Investors in Boca Raton (FL)
Photo of Steve Matheo, President at Access Industries
Steve Matheo
Sweet spot: $1.5M
Range: $100K - $5.0M